Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery

Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery

ObjectiveTo assess the efficacy and safety of camrelizumab plus different targeted drugs in adjuvant therapy after hepatocellular carcinoma (HCC) surgery.Patients and methodsThis retrospective cohort study included HCC patients who, after undergoing failed postoperative adjuvant lenvatinib therapy,...

Full description

Bibliographic Details
Main Authors: Xudan Wang, Weiwei Cao, Yan Qiu, Hongchen Ji, Juzheng Yuan, Weikang Wu, Fuyuan Liu, Liangyong Feng, Rui Ding, Xiao Li, Kaishan Tao
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
camrelizumab
targeted drugs
adjuvant therapy
survival
adverse events
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1174999/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1174999/full

Similar Items